Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

Widespread resistance to common antibiotics is increasing: WHO

Increasing resistance to essential antibiotics poses a growing threat to global health, with one...

Dopamine helps our brains to let go of memories

In a discovery that could reshape how we think about memory, researchers at Flinders University...

Vaccine for elephant herpesvirus found to be safe

The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...

Content from other channels on our network

ECD Turbidity Measurement Sensor

Partnership to create sustainable coupling relays

BMW launches EV battery recycling in Australia

$14K community grant provides water savings for school

Webinar to address EU packaging waste regulation

Report explores Australian perceptions of Medtech access

Vertical healing: redefining health care through high-rise hospital design

Using better network insight to boost productivity in Australian health care

Construction underway on new Redcliffe cancer care centre

Digital health lessons across industries

New PROeco II power supplies from Weidmüller: Built for reliability and scale

Pure Dairy opens manufacturing plant in Dandenong South

Siemens and NVIDIA preview technology for AI-era manufacturing

Lynas to expand heavy rare earths separation facility in Malaysia

Li-S Energy announces Australia’s first lithium foil production line